Landscape Capital Management L.L.C. cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 69.7% during the third quarter, Holdings Channel.com reports. The fund owned 6,875 shares of the medical research company’s stock after selling 15,819 shares during the period. Landscape Capital Management L.L.C.’s holdings in Edwards Lifesciences were worth $593,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in EW. BlackRock Inc. bought a new position in shares of Edwards Lifesciences in the second quarter valued at $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new stake in Edwards Lifesciences during the second quarter valued at about $11,168,000. Assenagon Asset Management S.A. boosted its holdings in shares of Edwards Lifesciences by 50.0% in the third quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company’s stock worth $234,727,000 after buying an additional 906,345 shares during the period. Conway Capital Management Inc. acquired a new position in shares of Edwards Lifesciences in the second quarter worth about $954,000. Finally, Commerce Bank purchased a new position in shares of Edwards Lifesciences in the second quarter worth approximately $3,121,000. Institutional investors own 79.46% of the company’s stock.
Wall Street Analyst Weigh In
EW has been the subject of several research analyst reports. Raymond James Financial increased their price objective on Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $115.00 target price on shares of Edwards Lifesciences in a report on Friday. Argus increased their price target on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. Jefferies Financial Group raised their price target on shares of Edwards Lifesciences from $102.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Finally, Leerink Partners boosted their price objective on shares of Edwards Lifesciences from $101.00 to $112.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $109.88.
Insider Buying and Selling at Edwards Lifesciences
In other news, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $104.25, for a total transaction of $64,530.75. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $4,173,544.50. The trade was a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald Bobo, Jr sold 48,900 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $103.05, for a total value of $5,039,145.00. Following the completion of the transaction, the vice president directly owned 22,798 shares of the company’s stock, valued at approximately $2,349,333.90. The trade was a 68.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 53,945 shares of company stock valued at $5,498,306 over the last quarter. 0.31% of the stock is currently owned by insiders.
Edwards Lifesciences Stock Performance
NYSE:EW opened at $101.87 on Friday. The firm’s 50-day moving average is $92.19 and its 200-day moving average is $86.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.86 and a current ratio of 4.60. Edwards Lifesciences Corporation has a 52-week low of $74.66 and a 52-week high of $108.00. The company has a market cap of $58.57 billion, a price-to-earnings ratio of 57.55, a PEG ratio of 2.86 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. Edwards Lifesciences’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.67 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current year.
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Read More
- Five stocks we like better than Edwards Lifesciences
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
